MedPath

Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies

Not Applicable
Conditions
Cancer
Registration Number
NCT02517281
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Brief Summary

The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
700
Inclusion Criteria
  • Patients with cancer beginning a targeted therapy
  • Patients able to follow the protocol
  • Age >/= 18 years old
  • Signed inform consent
Exclusion Criteria
  • Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
  • Pregnant or breastfeeding woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of clinical secondary effects bind to targeted therapiesEvery 28 days up to 5 years

Dermatological exam including questionnaire, clinical examination and photographies

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Gustave Roussy Cancer Campus Grand Paris

🇫🇷

Villejuif, Val De Marne, France

Gustave Roussy Cancer Campus Grand Paris
🇫🇷Villejuif, Val De Marne, France
Caroline Robert, MD
Principal Investigator
Thibaud Motreff
Contact
0142113730
thibaud.motreff@gustaveroussy.fr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.